JP2025508050A5 - - Google Patents
Info
- Publication number
- JP2025508050A5 JP2025508050A5 JP2024553353A JP2024553353A JP2025508050A5 JP 2025508050 A5 JP2025508050 A5 JP 2025508050A5 JP 2024553353 A JP2024553353 A JP 2024553353A JP 2024553353 A JP2024553353 A JP 2024553353A JP 2025508050 A5 JP2025508050 A5 JP 2025508050A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- acid sequence
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268967P | 2022-03-07 | 2022-03-07 | |
| US63/268,967 | 2022-03-07 | ||
| PCT/US2023/063795 WO2023172879A2 (en) | 2022-03-07 | 2023-03-06 | Multiplex gene edited cells for cd70-directed cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508050A JP2025508050A (ja) | 2025-03-21 |
| JP2025508050A5 true JP2025508050A5 (cg-RX-API-DMAC7.html) | 2026-03-12 |
Family
ID=87935884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553353A Pending JP2025508050A (ja) | 2022-03-07 | 2023-03-06 | Cd70指向性がん免疫療法のための多重遺伝子編集細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230390392A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4482872A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025508050A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023232083A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3254363A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023172879A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| CN117844811A (zh) * | 2024-03-08 | 2024-04-09 | 上海恒润达生生物科技股份有限公司 | 靶向敲除CD70基因的sgRNA组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030022311A1 (en) * | 1996-05-21 | 2003-01-30 | Dunnington Damien D. | Human CIS protein |
| US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US8067546B2 (en) * | 2005-04-19 | 2011-11-29 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
| DK3105317T3 (en) * | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| US11166985B2 (en) * | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP2021502077A (ja) * | 2017-11-06 | 2021-01-28 | エディタス・メディシン,インコーポレイテッド | 免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素 |
| US20210396739A1 (en) * | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20200063100A1 (en) * | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| KR20220100913A (ko) * | 2019-11-13 | 2022-07-18 | 크리스퍼 테라퓨틱스 아게 | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법 |
| WO2021108455A1 (en) * | 2019-11-25 | 2021-06-03 | KSQ Therapeutics, Inc. | Methods for activation and expansion of tumor infiltrating lymphocytes |
| CN115297890A (zh) * | 2020-02-03 | 2022-11-04 | 国立大学法人东海国立大学机构 | 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物 |
| MX2022015586A (es) * | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| JP7862361B2 (ja) * | 2020-07-29 | 2026-05-19 | ヤンセン バイオテツク,インコーポレーテツド | Hla-g抗原結合ドメインを含むタンパク質及びそれらの使用 |
-
2023
- 2023-03-06 EP EP23767591.3A patent/EP4482872A4/en active Pending
- 2023-03-06 CA CA3254363A patent/CA3254363A1/en active Pending
- 2023-03-06 AU AU2023232083A patent/AU2023232083A1/en active Pending
- 2023-03-06 WO PCT/US2023/063795 patent/WO2023172879A2/en not_active Ceased
- 2023-03-06 JP JP2024553353A patent/JP2025508050A/ja active Pending
- 2023-03-06 US US18/179,201 patent/US20230390392A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102777002B1 (ko) | 항글리피칸-3 항체 및 이의 응용 | |
| JP7595696B2 (ja) | Cd3抗原結合性断片及びその使用 | |
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| RU2748281C2 (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| AU2020202667A1 (en) | Cd20 binding molecules and uses thereof | |
| EP4039705A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| IL258491B2 (en) | Preparations and methods for inhibiting antigens of a particular lineage | |
| KR102086656B1 (ko) | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2010509931A5 (cg-RX-API-DMAC7.html) | ||
| JP2021511811A5 (cg-RX-API-DMAC7.html) | ||
| JP2020530306A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| WO2022222910A1 (zh) | 靶向gprc5d的抗体及其用途 | |
| HRP20110187T1 (hr) | Multispecifične deimunizirane tvari koje vežu cd3 | |
| JPWO2015146437A1 (ja) | 高機能性IgG2型二重特異性抗体 | |
| CN112955472A (zh) | 抗ptk7免疫细胞癌症疗法 | |
| CN117858906A (zh) | 与cldn18.2和cd3结合的双特异性结合剂 | |
| CN111620951B (zh) | EGFP-Wnt2融合蛋白抗原和Wnt2单克隆抗体以及Wnt2单克隆抗体的应用 | |
| US20220275081A1 (en) | Binding molecule specific for lrig-1 protein and use thereof | |
| KR20240046224A (ko) | 이중특이성 항체 및 그 용도 | |
| JP2023508674A5 (cg-RX-API-DMAC7.html) | ||
| CN101831434B (zh) | 抗人cd45ra鼠免疫球蛋白可变区基因及用途 | |
| US20060154334A1 (en) | Method of producing an antibody to epidermal growth factor receptor | |
| AU2369101A (en) | Antibodies against plasma cells |